Rentosertib Doses First Patient in China Phase III IPF Trial
Insilico Medicine reported first-patient enrollment and dosing in GENESIS-IPF-3, a 320-participant, 47-center China Phase III study of the oral TNIK inhibitor rentosertib in idiopathic pulmonary fibrosis. The 52-week randomized, double-blind, placebo-controlled trial uses annualized…
